Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.70 per share versus the Zacks Consensus Estimate of a loss of $1.68. This compares to loss of $2.68 per share a year ago. These ...
Wall Street expects a year-over-year decline in earnings on lower revenues when Sage Therapeutics, Inc. (SAGE) reports results for the quarter ended December 2024. While this widely-known consensus ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (SAGE), today announced that it will host a live webcast on Tuesday, February 11, 2025 at 4:30 p.m. ET to review fourth quarter and full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results